Dermagenics, U.S., Inc., a subsidiary of Greystone Pharmaceuticals, Inc. and the producer of Epi-Max®, an acetylated regenerated cellulose (ARC) sterile dressing for chronic wounds, is reporting pleasing (for the company) results, in the form of “very encouraging initial feedback” from clinical evaluators. The Epi-Max®, a medicated wound healing device, was covered by us last time about a year ago when it was approved by the FDA (see Epi-Max for Diabetic Skin Ulcers.)
From the press release, obtained by Medgadget:
Epi-Max®, cleared by the FDA for sale in the U.S.
in 2005, has created “very encouraging initial feedback” from clinical evaluations underway, according to Greg Pilant, CEO of Dermagenics, U.S., Inc…
Epi-Max, an acetylated regenerated cellulose (ARC) sterile wound dressing, is a prescription combination device that provides the benefits of an innovative wound dressing with dual active ingredients. It is indicated for use to manage pressure ulcers (stages I-IV), stasis ulcers, diabetic skin ulcers, skin irritations, cuts, and abrasions.
John H. Moore, MD and Medical Director of the Skaggs Wound Care Clinic in Branson, Missouri, cited that his center has been “very impressed” with initial results of their evaluation of Epi-Max.
“After just 2 weeks of a 6 week evaluation use of Epi-Max on the wounds of 10 of our most difficult-to-heal patients,” stated Dr. Moore, “we have seen an improvement in the quality of the wound bed tissue for all 10 patients and measurable healing in the majority.”
Not that we don’t share the enthusiasm of Dermagenics, but we would want to know if any of you have experience with this product that you want to share. Let us/other readers know!
The product page…
Flashback: Epi-Max for Diabetic Skin Ulcers